Current validity of diagnosis of permanent vegetative state: A longitudinal study in a sample of patients with altered states of consciousness.

Validez actual del diagnóstico de «estado vegetativo permanente»: estudio longitudinal en una muestra clínica de pacientes en estados alterados de conciencia.
Estado de mínima conciencia Estado de vigilia sin respuesta Estado vegetativo Longitudinal Minimally conscious scale Prognosis Pronóstico Unresponsive wakefulness syndrome Vegetative state

Journal

Neurologia
ISSN: 2173-5808
Titre abrégé: Neurologia (Engl Ed)
Pays: Spain
ID NLM: 101778590

Informations de publication

Date de publication:
Historique:
received: 30 12 2016
revised: 05 04 2017
accepted: 28 04 2017
pubmed: 18 7 2017
medline: 14 4 2020
entrez: 18 7 2017
Statut: ppublish

Résumé

Altered states of consciousness have traditionally been associated with poor prognosis. At present, clinical differences between these entities are beginning to be established. Our study included 37 patients diagnosed with vegetative state/unresponsive wakefulness syndrome (UWS) and 43 in a minimally conscious state (MCS) according to the Coma Recovery Scale-Revised (CRS-R). All patients were followed up each month for at least 6 months using the CRS-R. We recorded the time points when vegetative state progressed from 'persistent' to 'permanent' based on the cut-off points established by the Multi-Society-Task-Force: 12 months in patients with traumatic injury and 3 months in those with non-traumatic injury. A logistic regression model was used to determine the factors potentially predicting which patients will emerge from MCS. In the UWS group, 23 patients emerged from UWS but only 9 emerged from MCS. Of the 43 patients in the MCS group, 26 patients emerged from that state during follow-up. Eight of the 23 patients (34.7%) who emerged from UWS and 17 of the 35 (48.6%) who emerged from MCS recovered after the time points proposed by the Multi-Society-Task-Force. According to the multivariate regression analysis, aetiology (P<.01), chronicity (P=.01), and CRS-R scores at admission (P<.001) correctly predicted emergence from MCS in 77.5% of the cases. UWS and MCS are different clinical entities in terms of diagnosis and outcomes. Some of the factors traditionally associated with poor prognosis, such as time from injury and likelihood of recovery, should be revaluated.

Identifiants

pubmed: 28712840
pii: S0213-4853(17)30220-7
doi: 10.1016/j.nrl.2017.04.004
pii:
doi:

Types de publication

Journal Article

Langues

eng spa

Sous-ensembles de citation

IM

Pagination

589-595

Informations de copyright

Copyright © 2017 Sociedad Española de Neurología. Publicado por Elsevier España, S.L.U. All rights reserved.

Auteurs

E Noé (E)

Servicio de Neurorrehabilitación y Daño Cerebral, Hospitales Vithas-NISA, Fundación Hospitales Vithas-NISA, Valencia, España. Electronic address: quique@neurorhb.com.

J Olaya (J)

Servicio de Neurorrehabilitación y Daño Cerebral, Hospitales Vithas-NISA, Fundación Hospitales Vithas-NISA, Valencia, España.

C Colomer (C)

Servicio de Neurorrehabilitación y Daño Cerebral, Hospitales Vithas-NISA, Fundación Hospitales Vithas-NISA, Valencia, España.

B Moliner (B)

Servicio de Neurorrehabilitación y Daño Cerebral, Hospitales Vithas-NISA, Fundación Hospitales Vithas-NISA, Valencia, España.

P Ugart (P)

Servicio de Neurorrehabilitación y Daño Cerebral, Hospitales Vithas-NISA, Fundación Hospitales Vithas-NISA, Valencia, España.

C Rodriguez (C)

Servicio de Neurorrehabilitación y Daño Cerebral, Hospitales Vithas-NISA, Fundación Hospitales Vithas-NISA, Valencia, España.

R Llorens (R)

Servicio de Neurorrehabilitación y Daño Cerebral, Hospitales Vithas-NISA, Fundación Hospitales Vithas-NISA, Valencia, España; Neurorehabilitation and Brain Research Group, Instituto de Investigación e Innovación en Bioingeniería, Universitat Politècnica de València, Valencia, España.

J Ferri (J)

Servicio de Neurorrehabilitación y Daño Cerebral, Hospitales Vithas-NISA, Fundación Hospitales Vithas-NISA, Valencia, España.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH